In December 2018, atezolizumab in combination with bevacizumab and standard chemotherapy for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations was approved by the FDA. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.